Oncolys BioPharma Inc.
 
Licensing Executives Society (U.S.A. and Canada) Announces 2011 Deals of Distinction™ Awards
"The 5th Japan
Bio-Venture Award"

Award by Minister of Education, Culture, Sports, Science and Technology.
 
 
 
Oncolys is seeking partnering opportunities for our lead compounds. For more information visit our Partnering opportunities page on this site or contact us at anticancer@oncolys.com
Oncolys BioPharma is a privately held biopharmaceutical company focused on the development of novel biologics for the treatment of cancer and infectious disease.

We believe that through the development of replication-competent oncolytic virus and micrometastatic tumor diagnostic viruses, we produce safer, more effective, QOL-improving approaches aiming to revolutionize the current mode of cancer therapy.

Oncolys completed Phase-I clinical trial for Telomelysin, a replication-competent oncolytic virus, in the U.S. and plan to initiate Phase-I/II clinical study in Taiwan in collaboration with Medigen Biotechnology Corp. In addition to Telomelysin, Oncolys in-licensed oncology pipeline, YM753 (Oncolys code name: OBP-801) which has the potential to become best-in-class histone deacetylase (HDAC) inhibitor. Oncolys is conducting additional enabling preclinical studies and formulation development to file an IND.

Oncolys inlicensed exclusive worldwide rights of Festinavir, best-in-class potential NRTI from Yale University and completed phase Ia in the US and phase Ib/IIa clinical study in France. With a promising clinical safety and efficacy data obtained at phase Ib/IIa study, Oncolys succeeded to conclude an exclusive worldwide licensing agreement with Bristol-Myers Squibb. In addition to Festinavir, Oncolys antiviral pipeline includes a new class of anti-hepatitic-C-virus (HCV) agent in early research stage having new mechanism of action.

As a diagnostic/tumor marker agent, Oncolys is currently developing TelomeScan® (OBP-401), which is at feasibility assessment stage and is expected to be a first and best-in-class diagnostic agent in detecting various types of living and circulating tumor cells (CTC) in the blood.
| HOME |
Copyright (c)2004-2005, Oncolys BioPharma Inc. All rights reserved.